News
AEMD
1.310
-9.03%
-0.130
Recap: Aethlon Medical Q1 Earnings
  Aethlon Medical (NASDAQ:AEMD) reported its Q1 earnings results on Tuesday, August 9, 2022 at 04:15 PM. Here's what investors need to know about the announcement.
Benzinga · 8h ago
Aethlon Medical GAAP EPS of -$0.19 beats by $0.03
Aethlon Medical press release (<span class="ticker...
Seekingalpha · 15h ago
Aethlon Medical Q1 EPS $(0.19) Beats $(0.22) Estimate
Aethlon Medical (NASDAQ:AEMD) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.22) by 13.64 percent. This is a 18.75 percent decrease over losses of $(0.16) per share from
Benzinga · 15h ago
Aethlon Medical to Release First Quarter Financial Results and Host Conference Call on August 9, 2022
Aethlon Medical, Inc. (Nasdaq: AEMD), a company developing medical therapeutics to treat cancer and life-threatening infectious disease, today announced that it will issue financial results for its first quarter ended June 30, 2022, at 4:15 p.m. EST on Tue...
PR Newswire · 6d ago
BNGO, NTLA and OPTT are among pre market gainers
Applied DNA Sciences (APDN) +116%. Poseida Therapeutics (<a ...
Seekingalpha · 6d ago
Short Volatility Alert: Aethlon Medical, Inc.
On Monday, shares of Aethlon Medical, Inc. (NASDAQ: AEMD) experienced volatile short activity. After the activity, the stock price went up +38.00% to $1.38. The overall sentiment for AEMD has been Bearish.
Benzinga · 08/02 14:58
AEMD,GMDA and QNRX are among pre market gainers movers
AMTD IDEA (AMTD) +323%. 36Kr Holdings (<a href="https://seekingalpha.co...
Seekingalpha · 08/02 12:30
California Declares State of Emergency over Monkeypox Outbreak
-CNBC https://www.cnbc.com/2022/08/01/california-declares-a-state-of-emergency-over-monkeypox-outbreak.html
Benzinga · 08/02 00:27
Virax, Aethlon top healthcare gainers; while Otonomy, Kazia lead losers' pack
Gainers: Virax Biolabs VRAX +62%. Aethlon Medical (AEMD) <f...
Seekingalpha · 08/01 14:00
AVXL, WATT and SOL are among pre market gainers
GeoVax Labs (GOVX) +57%. Mobile Global Esports (MGAM) <font color="gr...
Seekingalpha · 08/01 12:33
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Benzinga · 08/01 12:16
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Investor Place · 08/01 11:30
Aethlon Medical Announces Publication of Peer-Reviewed Journal Article Describing Hemopurifier Resin Binding of Seven COVID-19 Variants
Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to diagnose and treat cancer and life threatening infectious diseases, today announced the publication of a peer-reviewed journal article in PLOS ONE. The ar...
PR Newswire · 07/28 18:01
Monkeypox A Nationally Notifiable Condition, CDC Poised To Announce: Report
Benzinga · 07/28 12:06
INO, MP and FAZE are among pre market gainers
Zymergen (ZY) +40%<a href="https://seekingalpha.com/news/3859925-dna-stock-on-watch-...
Seekingalpha · 07/25 12:29
Aethlon Medical Secures FDA Clearance For Amendment In Initial-Stage COVID-19 Study
The U.S. Food and Drug Administration (FDA) has approved an amendment to the protocol of the ongoing clinical trial investigating Aethlon Medical’s (NASDAQ: AEMD) lead therapy Aethlon Hemopurifier for patients with severe COVID-19.
Benzinga · 07/11 15:41
FDA approves protocol change in Aethlon's trial of its purifier to treat severe COVID
Aethlon Medical (NASDAQ:AEMD) on Monday <a href="https://se...
Seekingalpha · 07/11 13:31
BRIEF-Aethlon Medical Announces U.S. FDA Approval Of Hemopurifier Covid-19 Study Protocol Amendment
BRIEF-Aethlon Medical Announces U.S. FDA Approval Of Hemopurifier Covid-19 Study Protocol Amendment
Reuters · 07/11 12:11
Aethlon Medical Announces U.S. FDA Approval of Hemopurifier COVID-19 Study Protocol Amendment
Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to diagnose and treat cancer and life threatening infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved an amend...
PR Newswire · 07/11 12:01
Aethlon Medical Receives FDA Approval to Eliminate Dialysis Treatment as Requirement for Hemopurifier COVID-19 Study
MT Newswires · 07/11 10:44
More
Webull provides a variety of real-time AEMD stock news. You can receive the latest news about Aethlon Medical through multiple platforms. This information may help you make smarter investment decisions.
About AEMD
Aethlon Medical, Inc. (Aethlon) is a biotechnology company. The Company is focused on developing products to diagnose and treat life and organ-threatening diseases. It is involved in developing the Hemopurifier, a therapeutic blood filtration system indicated for infectious diseases and cancer. The Company operates through two segments: Aethlon and ESI. The Aethlon segment represents its therapeutic business activities. The ESI segment represents its diagnostic business. In cancer, the Hemopurifier is designed to deplete the presence of circulating tumor-derived exosomes that promote immune suppression, seeding the spread of metastasis. The Company is conducting clinical trials in patients with advanced and metastatic head and neck cancer. It is focused on the treatment of solid tumors that are being treated with checkpoint inhibitors. Hemopurifier have been used to treat individuals infected with human immunodeficiency virus (HIV), hepatitis C virus (HCV), and Ebola.